AER 1637842 is a spontaneous case, received on 22/Sep/2015 from a physician and concerns a patient of 
unknown demographics who developed progressive multifocal leukoencephalopathy (PML) whilst being treated 
with rituximab (Mabthera).
No medical history, past drugs, concurrent conditions and concomitant medications were reported.
On an unspecified date, the patient started therapy with rituximab for unknown indication (route, dose and 
frequency not reported). On an unspecified date, the patient developed progressive multifocal 
leukoencephalopathy.
At the time of this report, outcome of progressive multifocal leukoencephalopathy was not reported. It was unknown
if the therapy with rituximab was ongoing or not.
Print Time: 13-JUN-2016 09:36 AM If a field is blank, there is no data for that field Page 455 of 457
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The reporter did not assessed the causality for progressive multifocal leukoencephalopathy with rituximab.
The company assessed the event progressive multifocal leukoencephalopathy as medically significant.
No further information was provided.